Scientists test live oral vaccine to fight two major causes of Traveler's diarrhea
NCT ID NCT04634513
Summary
This early-stage study tested a new oral vaccine designed to protect against two common bacterial causes of traveler's diarrhea: Shigella and certain E. coli strains. Researchers gave 53 healthy adults either the vaccine or a placebo to check for safety and see if it triggered an immune response. The study focused on monitoring side effects and measuring how the body reacted to the vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLA INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.